Name: ONC Income Statement - Beone Medicines Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ONC - Beone Medicines Ltd.

USD | NASDAQ | Healthcare

ONC Income Statement - Beone Medicines Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	1,513.4	1,498.2	1,412.3	1,315.3	1,117.3	1,127.8	1,001.6	929.2	751.7	634.4	781.3	595.3	447.8	380.1	387.6	341.6

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014
Revenues
Revenues	5,739.2	5,343.0	3,810.2	2,458.8	1,415.9	1,176.3	308.9	428.2	198.2	238.4	1.1	8.8	13.0
Cost of Revenue	-	-	-	-	286.5	164.9	70.7	71.2	28.7	5.0	0.0	-	-
Gross Profit	-	-	-	-	1,129.4	1,011.4	238.2	357.0	169.5	233.4	1.1	-	-
Operating Expenses
Research & Development	2,205.2	2,145.9	1,953.3	1,778.6	1,640.5	1,459.2	1,294.9	927.3	679.0	269.0	98.0	58.3	21.9
Selling General & Administrative
Operating Income
Operating Income	685.9	447.1	(568.2)	(1,207.7)	(1,789.7)	(1,438.7)	(1,657.7)	(959.9)	(705.8)	(98.5)	(117.1)	(56.7)	(15.8)
Non-Operating
Interest Income	-	70.5	69.6	78.4	-	-	-	-	-	-	-	-	-
Interest Expense	84.1
Tax & Net
Income Tax Expense	142.1	129.9	111.8	55.9	42.8	19.2	10.4	7.0	(15.8)	2.2	0.1	0.0	0.0
Net Income From Continuing Ops
Per Share
EPS Basic	0.36	0.20	(0.47)	(0.65)	(1.49)	(1.21)	(1.50)	(1.22)	-	-	-	-	-
EPS Diluted	0.34
Supplementary Data
EBITDA	836.0	588.8	(396.4)	(1,120.1)	(1,723.4)	(1,392.3)	(1,625.9)	(941.3)	(695.4)	(93.7)	(115.2)	(55.2)	(14.2)
EBIT	685.9

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	541.2	615.4	523.7	524.9	481.9	542.0	496.2	454.5	460.6	494.0	453.3	422.8	408.6	446.0	426.4	378.2	389.9	430.5	351.9	356.1	320.7	355.5	349.1	286.0	304.3	283.3	237.0	228.8	178.4	257.5	147.6	164.3	109.7	91.3	87.7	47.2	42.8	28.9	30.1	21.1
Selling General & Administrative	555.1	555.3	529.0	537.9	459.3	504.7	455.2	443.7	427.4	418.8	365.7	395.0	328.5	329.7	322.9	331.4
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	41.1	43.3	35.7	29.9	32.8	52.7	70.0	23.8	25.3	27.1	19.2	21.3	20.0	20.0	15.2	14.5
Amortization of Intangibles	1.8	1.6	1.6	5.8	1.2	1.2	1.3	1.2	1.2	3.0	2.3	1.0	1.0	1.0	1.0	1.0	1.0
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	1,096.3	1,170.7	1,052.7	1,062.8	941.2	1,046.7	951.4	898.2	888.1	912.4	819.0	818.0	737.3	562.2	826.0

Operating Income
Operating Income	249.9	185.0	163.1	87.9	11.1	(79.4)	(120.3)	(107.2)	(261.3)	(383.8)	(134.0)	(318.7)	(371.3)	(468.6)	(438.4)	(439.4)	(443.3)	(571.7)	(462.3)	(474.8)	70.2	(484.9)	(440.1)	(358.9)	(373.8)	(388.0)	(312.3)	(85.8)	(173.8)	(280.8)	(151.1)	(163.1)	(110.8)	(103.8)	114.9	(58.0)	(51.5)	(37.3)	(34.8)	(24.6)

Non-Operating
Interest Income	27.7	-	-	-	12.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.2	0.3
Interest Expense	32.9	26.5	12.7	12.0	7.0	(18.1)	14.3	13.2	12.4	(11.7)	6.6	4.9	4.6	5.1	5.6	5.5	5.5	7.1
Income From Equity Investments	-	-	(0.6)	(1.9)	(13.4)	-	(2.9)	(4.0)	(0.9)	-	(2.7)	-	(0.2)	-	-	-
Other Non-Operating Income	14.5	(35.7)	(19.0)	8.2	4.0	(13.7)	11.3	(12.0)	1.8	16.7	336.7	(63.8)	18.3	19.4	(125.6)	(129.6)	12.0
Pre-Tax Income	259.2	149.2	147.2	99.5	20.9	(85.4)	(98.3)	(105.9)	(243.4)	(350.8)	229.3	(367.5)	(336.9)	(431.0)	(551.2)	(557.6)

Tax & Net
Income Tax Expense	31.9	82.7	22.3	5.2	19.6	66.5	23.0	14.5	7.7	16.8	13.9	13.7	11.5	14.4	6.3	8.1	13.9	19.1	5.0	(0.2)	(4.6)	18.7	(8.4)	(1.5)	1.6	7.6	(3.2)	2.1	0.5	(8.5)	(0.5)	(3.4)	(3.4)	4.9	(3.1)	0.2	0.2	(0.3)	0.1	0.1
Net Income From Continuing Ops	227.4	66.5	124.8	94.3	1.3	(151.9)	(121.4)	(120.4)	(251.2)	(367.6)	215.4	(381.1)	(348.4)	(445.3)	(557.6)	(565.7)	(435.2)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	227.4	66.5	124.8	94.3	1.3	(151.9)	(121.4)	(120.4)	(251.2)	(367.6)	215.4	(381.1)	(348.4)	(445.3)	(557.6)	(565.7)	(435.2)
Net Income Attributable To Parent	227.4	66.5	124.8	94.3	1.3	(151.9)	(121.4)	(120.4)	(251.2)	(367.6)	215.4	(381.1)	(348.4)	(445.3)	(557.6)	(565.7)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	227.4	66.5	124.8	94.3	1.3	(151.9)	(121.4)	(120.4)	(251.2)	(367.6)	215.4	(381.1)	(348.4)	(445.3)	(557.6)

Per Share
EPS Basic	0.16	-	0.09	0.07	0.00	-	(0.09)	(0.09)	(0.19)	-	0.16	(0.28)	(0.26)	-	(0.41)	(0.42)	(0.33)	-	(0.36)	(0.40)	0.06	-	(0.37)	(0.33)	(0.36)	-	-	-	-	-	(0.19)	-	-	-	0.21	-	-	-	(0.08)	-
EPS Diluted	0.15	-	0.08	0.06	0.00	-	(0.09)	(0.09)	(0.19)	-	0.15	(0.28)	(0.26)	-	(0.41)	(0.42)	(0.33)	-
Shares Basic	1,442.5	-	1,432.8	1,408.2	1,390.1	-	1,376.8	1,361.1	1,355.5	-	1,360.7	1,360.2	1,354.2	-	1,345.3	1,336.5	1,332.0	-
Shares Diluted	1,505.0	-	1,488.8	1,463.3	1,445.3	-	1,376.8	1,361.1	1,355.5	-	1,390.3	1,360.2	1,354.2	-	1,345.3	1,336.5	1,332.0	-

Supplementary Data
EBITDA	291.0	228.3	198.8	117.7	43.9	(26.7)	(50.2)	(83.4)	(236.1)	(356.7)	(114.7)	(297.4)	(351.2)	(448.6)	(423.1)	(424.9)	(426.7)	(557.9)	(450.6)	(463.6)	79.8	(476.7)	(432.0)	(351.2)	(366.0)	(379.9)	(308.6)	(82.5)	(170.3)	(277.0)	(148.9)	(161.0)	(108.6)	(101.7)	116.1	(57.5)	(50.7)	(36.8)	(34.3)	(24.1)
EBIT	249.9	185.0	163.1	87.9	11.1	(79.4)	(120.3)	(107.2)	(261.3)	(383.8)	(134.0)	(318.7)	(371.3)	(468.6)	(438.4)	(439.4)	(443.3)	(571.7)	(462.3)